Long-term treatment with JAK2 inhibitors such as fedratinib or ruxolitinib has been observed to lower JAK2 V617F VAFs in myelofibrosis (MF) patients, correlating with clinical improvements like reduced spleen size and decreased recurrence post-transplant [72,73]. This evidence concerns the gene JAK2 and myelofibrosis.